The CA Profile©
Dr. Emil K. Schandl, M.S. Ph.D.,FACB, SC (ASCP), CC (NRCC), LNC, CLD, a Clinical Biochemist and Oncobiologist with Metabolic Research, a 501(c)(3) not for profit biomedical research corporation, and American Metabolic Laboratories, has developed a battery of blood tests designed to predict your risk of developing cancer (CA) long before detectible symptoms may occur. These tests have proven to be excellent for monitoring individuals receiving non-toxic or toxic treatments. In order to be able to realize actual therapeutic progress, it is recommended to perform the Profile before, during, and at the conclusion of a certain therapy. If the markers decrease, that is a very good sign of healing. The CA Profile© includes intact HCG and HCG-beta, core, and fragments, PHI (phosphohexose isomerase), GGTP (gamma glut amyl transpeptidase) enzymes, CEA (carcinoembryonic antigen), TSH (thyroid stimulating hormone), and DHEA-S (dehydroepiandrosterone). The HCG hormone (human chorianic gonadotropin) and its fragments are generally made by the embryonic origin trophoblast cells. It is present in a high percentage of any type of cancer. Two different methods are being used to confirm the validity of the often very low amount of the hormone in the blood. One is immunoradiometric assay, i.e. IRMA and the other one is chemiluminescence, i.e. IMM. Both of these methodologies are extremely sensitive and will detect very minute quantities of the hormone. Dr.Schandl named this tumor marker the pregnancy and "malignancy hormone." HCG suppresses the immune system and generally it is produced under anaerobic cellular conditions by the trophoblast.
Recently, HCG - URINE Test was studied and introduced at American Metabolic Laboratories. This test is not a constituent of the Cancer Profile, however, it can be ordered at a discount price when with it, or on its own. It must be noted that American Metabolic Laboratories' Urine-HCG Test is the one and only one of its kind for being quantitative down to 1.1 mIU/mL. This test, unlike Doctor Navarro's for instance, requires about 0.5 mL of urine without any treatment, in its natural form. It is totally specific for the HCG hormone even in minute quantities. The old method requires acetone denaturation and extraction of HCG, LH, FSH, and TSH hormones. All of the four structurally very similar hormones are precipitated by the harsh treatment and will add on to the reported HCG value. Postmenopausal women and older men with high LH and/or FSH, and hypothyroid individuals with high TSH will yield elevated "HCG" values.
Consider the fact, testing for HCG alone can result in approximately 30% false negative results. The entire Cancer Profile© may miss only 10% cancer positive patients.
PHI is the enzyme that channels cells into anaerobic metabolism, i.e. fermentation. This kind of cellular survival is what cancer cells favor. The more energy generating metabolic pathway is oxidative phosphorilation. This is the pathway normal cells require in the presence of oxygen. Hence, more oxygen is less cancer and less oxygen is more cancer. PHI is called the autocrine motility factor, i.e. malignancy or spread factor.
CEA is a broad spectrum cancer marker. It is the carcinoembryonic antigen. It can also be elevated in all sorts of cancers. It is very prevalent in cancers of the breast and may be the colon. Like all the others, it is an independent cancer marker that by itself may or may not score.
GGTP is the most sensitive test for the liver, however, it may be elevated in diseases of the heart, lungs, and kidneys. It is not a tumor marker. However, it may be elevated in cancer patients as a result of either cancer spread or toxic therapy.
TSH or thyroid stimulating hormone regulates metabolic rate, i.e. oxygen utilization. A high level, i.e. hypothyroidism, may be a prelude to cancer. Chemotherapy frequently causes this anaerobic condition.
DHEA-S is the adrenal anti stress, pro immunity, longevity hormone. The immune system is impaired without adequate amounts of this hormone. Most if not all cancer patients and those in the process of developing cancer have very low or none DHEA in their blood.
Dr. Schandl also suggests a PTH (parathyroid hormone) test to evaluate calcium status in the bones.
For a much more complete work up, you may want to consider the Longevity Profile ©
The CA Profile© may yield 85-93 positives out of 100 pathologically established malignancies. Because of its capacity to foretell the development of cancer years before a tumor is apparent, a positive finding may be a serious warning sign of a developing cancer. The CA Profile© test also can be used to monitor the response of cancer patients to various therapies: an increasing or decreasing value of a tumor marker may indicate the futility or benefits of a therapy.
Also, the CA Profile© can be combined with specific cancer tests, such as the PSA, CA 15.3 (to detect breast cancer), CA 125 (to detect ovarian cancer), and CA 19.9 (for pancreatic or gastric cancer) to provide the most complete picture of your risk and/or the status of almost every cancer.
Cancer may actually be the number-one killer of humans on the North American continent. Whereas there is no certain cure for cancer, it may be preventable. Fortunately, in most cases, treatments and therapies can successfully extend life for many years. It is essential for cancer patients and their physicians to know how a person is responding to therapy. Biochemical tests are the quickest and most sensitive heralds in this respect.
Persons, who appear to be healthy may be harboring growing, developing cancer cells without any physical signs or symptoms. In other words, no diagnosis can be made by X-ray, CT scan, MRI,or other established methods. The importance of early diagnosis, made possible by biochemical tests, cannot be overemphasized.
The CA Profile©, together with a chemistry profile (SMAC or similar), CBC with differential and platelet count, PTH for the evaluation of calcium metabolism, etc., see the Longevity Profile. PSA for men over 40, or CA 125 (ovary) and CA 15.3 (breast) for women, and CA 19.9 (gastric/pancreatic) for both genders, is the most comprehensive evaluation available for prevention, early detection, and therapeutic monitoring of cancerous metabolic disorders.
Dr. Schandl has tested tens of thousands of patients. The results of these tests not only indicate whether or not cancer is present, but also measure the fluctuating conditions of the patient. Obviously, this capacity is essential for assessing the effectiveness of the therapy instituted.
Early diagnosis may add years of precious human life via prompt attention to the developing problem.
Even though our scientists consider the CA Profile© to be the most comprehensive of its kind, a negative score does not entirely rule out the presence of cancer. It does, however, provide a reasonable degree of confidence.
The blood usually carries messages of ill health before such a condition could be detected by any other method. However, it should be mentioned that the final, definitive diagnosis for cancer is tissue/cell examination by a pathologist. The CA Profile© is a very powerful tool as a part of a diagnostic work up. A positive value may suggest, sometimes strongly, the presence or the process of developing a cancer. The tests, in general, are not organ-specific.
The CA ProfileŠ tests are the following:
Tests Also Recommended:
A Letter From Dr. Schandl
I designed the CA Profile© while in the nuclear medicine department of a large hospital. My work was to inject people with radioactive substances for the performance of various scans: brain, bone, liver, kidney, heart, lung, etc. I felt very uncomfortable making people radioactive for the tests, touching the radioactive materials, and having to be near the radiated, injected people.
The doses used were well within acceptable limits by all regulatory agencies. However, I have always maintained there is no such thing as safe radiation. So, having an excellent background in clinical chemistry, radiation biology, biochemistry, biology, genetics, and enzymology, I composed the CA Profile©. It is made up of various tests. It is not invasive or radioactive. It requires no radioactive substances nor any x-rays, CAT scan radiation, or even nuclear magnetic imaging (MRI). MRI involves speedy resonance of hydrogen atom protons due to an induced electromagnetic field, which is 3,000 to 25,000 times that of our Earth's own field.
No surgical manipulations are required or used. Most commonly used diagnostic modalities can potentially cause cancer themselves. A recent issue concerning mammograms is an example. There is also considerable information on the carcinogenic effects of high-energy, high-frequency magnetic (or any) radiation.
The CA Profile© is simply composed of blood tests. The only invasiveness is the prick of a needle. To assure specimen stability, samples must be handled strictly as instructed. Tests are performed weekly and results reported on Fridays. Thus, early detection and monitoring of cancers is reliably achieved. The CA Profile© is being used by many doctors in the U.S., as well as in Europe, Canada, South America, Asia, the Philippines, and the Atlantic island communities.
Many years of testing showed that accuracy can be as high as 90-93%. This means that of 100 established active cancer cases 90-93 may yield positive test results. Do not forget, however, the absolute final diagnosis is a biopsied specimen; that is, a tissue pathology. A positive test result may warrant a complete change of lifestyle through metabolic therapy. Your M.D., D. O., N. D.,chiropractor, podiatrist, or dentist, acupuncure physician, or our staff physician can order the tests.
Sincerely yours in health,
Dr. Emil K. Schandl
Blood testing is an important and exacting science. Interpretations depend on the knowledge and expertise of trained clinical scientists. Therefore, it is recommended that you work closely with your physician or other qualified health professional for a satisfactory outcome. Dr. Schandl is available to interpret the test results for no additional charge.
Test availability: To order blood tests by mail, call us:
1. 954. 929. 4814